Developmental Funds support the Lineberger Comprehensive Cancer Center (LCCC) mission directly through the provision of resources and indirectly by leveraging institutional and philanthropic assets. Collectively, these resources expand and enhance cancer research across LCCC in the basic, clinical, population and translational sciences. During the last five years, these funds have been used to make key recruitments, to launch innovative ideas, and to make technical advances within our Shared Resources. Through these expenditures, the LCCC bolstered interdisciplinary and translational research efforts. By objective criteria, e.g. extramural grants funded, and junior faculty garnering national awards, our recruitment and retention efforts have been a stunning success. Our range of pilot project awards have initiated new research across the clinical, population, translational, and basic spectrum, again yielding success in seeding extramural grant funding, broad collaborations, and cancer related publications. The funds provided for Shared Resources have developed new techniques, particularly those translating fundamental discoveries into clinical applications. A decision by NCI three years into this cycle allowed expenditures of Developmental Funds for projects outside the borders of the United States. We were please to utilize this capability to fund pilot projects in our initiatives in sub-Saharan Africa that have led to significant NCI grant funding. While we retained the capability of using Developmental Funds for bridge funding, we did not utilize any Development Funds for this in the last cycle. As has been the case over the last decade, Developmental Funds have been key in the growth of the Center's scientific and clinical impact. LCCC requests $50,000 increase in this category, to $700,000 per year, in this renewal application, justified by past success and needs for a growing Center. We will continue to use these funds in recruitment, pilot projects, and Shared Resource development and retain the potential for interim (bridge) funding.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA016086-43
Application #
9614899
Study Section
Subcommittee I - Transistion to Independence (NCI)
Project Start
Project End
Budget Start
2018-12-01
Budget End
2019-11-30
Support Year
43
Fiscal Year
2019
Total Cost
Indirect Cost
Name
University of North Carolina Chapel Hill
Department
Type
DUNS #
608195277
City
Chapel Hill
State
NC
Country
United States
Zip Code
27599
Moschos, Stergios J; Sullivan, Ryan J; Hwu, Wen-Jen et al. (2018) Development of MK-8353, an orally administered ERK1/2 inhibitor, in patients with advanced solid tumors. JCI Insight 3:
Brosnan, Evelyn M; Anders, Carey K (2018) Understanding patterns of brain metastasis in breast cancer and designing rational therapeutic strategies. Ann Transl Med 6:163
Valle, Carmina G; Queen, Tara L; Martin, Barbara A et al. (2018) Optimizing Tailored Communications for Health Risk Assessment: A Randomized Factorial Experiment of the Effects of Expectancy Priming, Autonomy Support, and Exemplification. J Med Internet Res 20:e63
Sun, Junjiang; Shao, Wenwei; Chen, Xiaojing et al. (2018) An Observational Study from Long-Term AAV Re-administration in Two Hemophilia Dogs. Mol Ther Methods Clin Dev 10:257-267
Wilczewski, Caralynn M; Hepperla, Austin J; Shimbo, Takashi et al. (2018) CHD4 and the NuRD complex directly control cardiac sarcomere formation. Proc Natl Acad Sci U S A 115:6727-6732
Waters, Andrew M; Der, Channing J (2018) KRAS: The Critical Driver and Therapeutic Target for Pancreatic Cancer. Cold Spring Harb Perspect Med 8:
Cai, Ling; Tsai, Yi-Hsuan; Wang, Ping et al. (2018) ZFX Mediates Non-canonical Oncogenic Functions of the Androgen Receptor Splice Variant 7 in Castrate-Resistant Prostate Cancer. Mol Cell 72:341-354.e6
Au, Kin Man; Tripathy, Ashutosh; Lin, Carolina Pe-I et al. (2018) Bespoke Pretargeted Nanoradioimmunotherapy for the Treatment of Non-Hodgkin Lymphoma. ACS Nano 12:1544-1563
Mirlekar, Bhalchandra; Michaud, Daniel; Searcy, Ryan et al. (2018) IL35 Hinders Endogenous Antitumor T-cell Immunity and Responsiveness to Immunotherapy in Pancreatic Cancer. Cancer Immunol Res 6:1014-1024
Buist, Diana S M; Abraham, Linn; Lee, Christoph I et al. (2018) Breast Biopsy Intensity and Findings Following Breast Cancer Screening in Women With and Without a Personal History of Breast Cancer. JAMA Intern Med 178:458-468

Showing the most recent 10 out of 1525 publications